Chi-Med and Nestlé Form JV to Develop Chi-Med’s Lead Drug Candidate

Hutchison Chi-Med and Nestlé announced the formation of a major new JV based on Chi-Med’s expertise in traditional Chinese medicines. The JV, which will be called Nutrition Science Partners Limited, will focus on innovative gastrointestinal TCM-based medicines and nutritional products. Although the description sounds like an OTC venture, it also includes Chi-Med’s lead drug candidate, HMPL-004, a TCM-derived drug. HMPL-004 will soon begin Phase III trials as a treatment for ulcerative colitis and Crohn’s disease. More details.... Stock Symbol: (AIM: HCM) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});